Role of intestinal microbiota in cardiovascular disease risk in end stage renal disease patients

Okba, Ashraf Mahmoud; Shahin, Rasha Mohamad Hosny; Baki, Aber Halim; Sheha, Dina Sayed; Farag, Mohamed Mekawy Motaz

doi:10.4172/clinical-practice.1000396

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genus Lactobacillus belongs to Lactic acid bacteria, generally are considered to be bene cial microorganisms and have been associated with multiple potential health effects in both humans and animals 50 . However, a study from Egypt nd the Lactobacillus is signi cantly higher in CKD patients than healthy control, and moreover, the Lactobacillus is higher in CKD with cardiovascular disease (CVD) than CKD without CVD, suggesting Lactobacillus could not provide renal protective effect 51 . The current study showed that the average abundance of lactobacillus is almost ve times higher in IMN group than healthy control, consistent with study from Egypt, and GLM analysis also suggest it is pathogen for IMN.…”

Section: Discussionmentioning

confidence: 99%

Altered Intestinal Microbial Flora and Abnormal Metabolism in Chinese Patients With Idiopathic Membranous Nephropathy

Shi¹,

Li²,

Lin³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Dysbiosis of the intestinal microbiome and related metabolites have been observed in chronic kidney disease (CKD), yet their roles in idiopathic membranous nephropathy (IMN) is poorly understood. Results: In this study, we describe the variation of intestinal bacteria and fecal metabolites in patients with IMN for the first time in Chinese population. Stool samples are collected from 41 IMN patients at the beginning of diagnosis confirmation and 41 gender and age matched healthy control (HC). Microbial communities are investigated by sequencing of 16S rRNA genes and functional profiles predicted using Tax4Fun, and the correlation between intestinal bacteria and IMN clinical characteristics is also analyzed. Untargeted metabolomic analysis is performed to explore the relationship between colon’s microbiota and fecal metabolites. IMN gastrointestinal microbiota demonstrates lower richness and diversity compared to HC, and exhibits a marked taxonomic and inferred functional dysbiosis when compared to HC. Some genera are closely related to the clinical parameters, such as Citrobacter and Akkermansia. 20 characteristic microbial biomarkers are selected to establish a disease prediction model with a diagnostic accuracy of 93.53%. Fecal metabolomics shows that tryptophan metabolism is reduced in IMN patients but uremic toxin accumulation in feces is not noticeable. Fecal microbiota transplantation demonstrates that gut dysbiosis impairs gut permeability in microbiota-depleted mice and induces NOD-like receptor activation in kidneys. Conclusions: Clarifying the changes in intestinal microbiota in IMN patients will help further know the pathogenesis of this disease, and microbiota-targeted biomarkers will provide a potentially powerful tool for diagnosing and treating IMN.

show abstract

Section: Discussionmentioning

confidence: 99%